Clinical Progress Update From PRO-101, a Hybrid Phase One Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Prosetin in Participants With ALS (P10-9.007)

Erin Fleming; Kristiana Salmon; April Ruby; Hilde Williams; Ingela Danielsson-Sanden

doi:10.1212/wnl.0000000000217069

June 9, 2026Neurology

Clinical Progress Update From PRO-101, a Hybrid Phase One Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Prosetin in Participants With ALS (P10-9.007)

View at Publisher

Ask AI

Bookmark

Share

Key Points

The aim is to assess the safety and effectiveness of prosetin in treating ALS.
Hybrid Phase 1 study design
Evaluated prosetin's safety, tolerability, pharmacokinetics, and pharmacodynamics
Participants diagnosed with ALS
Results on safety and tolerability were monitored, but specific numerical data were not provided.
Pharmacokinetics and pharmacodynamics were evaluated to assess prosetin's action in the body.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Hybrid Phase 1 trial evaluates prosetin's safety and pharmacokinetics in ALS participants, indicating its potential role in treatment.

Abstract

Study PRO-101 is a hybrid Phase 1 study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of prosetin in participants with ALS.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Fleming et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf36efaef96ed7f055de6 https://doi.org/10.1212/wnl.0000000000217069

View at Publisher

Ask AI

Bookmark

Share

Clinical Progress Update From PRO-101, a Hybrid Phase One Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Prosetin in Participants With ALS (P10-9.007)

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Clinical Progress Update From PRO-101, a Hybrid Phase One Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Prosetin in Participants With ALS (P10-9.007)

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading